ClinicalTrials.gg
RecruitingNCT06636240Updated May 25, 2025

Prebiotic Effects of Mulberry Fruit in Children and Adolescents With Atopic Dermatitis

An interventional study of Mulberry fruit juice and Mometasone furoate 0.1% cream in Atopic Dermatitis (Eczema) and Atopic Dermatitis, Probiotics, sponsored by Taipei Medical University Shuang Ho Hospital. Recruiting at 2 sites in Taiwan. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-05-25.

Sponsored by Taipei Medical University Shuang Ho Hospital · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 70 studies in Dermatitis, Atopic with a site in Taiwan — 10 open to participants now, 21 under way, 8 of them phase 3. Dermatitis, Atopic · Taiwan.

Planned enrollment
40th of 60
120 · median 290
Started
2025
with 2 others
No phase
9 of 70
4 open now
Primary completion
2026-02
later than 4 of 20 live
Registered
62nd of 70
by date

Among the 70 studies in Dermatitis, Atopic with a site in Taiwan, this one is the 40th largest by planned enrollment of the 60 interventional ones that give a count, is one of 3 that started in 2025, is one of 9 with no phase, reaches primary completion later than 4 of the 20 other live ones, and was the 62nd registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

10 of the 70 studies in Dermatitis, Atopic with a site in Taiwan are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Dermatitis, Atopic with a site in Taiwan, or all of them as a file.
02

Study summary

This project proposes a randomized controlled human study to explore the prebiotic effects of consuming mulberry juice on atopic dermatitis in children and adolescents. The study aims to investigate the potential of mulberry fruit as a human prebiotic. This human study will recruit up to 120 participants from the Taipei Medical University Hospital (commissioned by the Ministry of Health and Welfare). Participants will be divided into experimental groups and a control group, with a 3-month intervention involving five clinical assessments and three stool collections. The goal is to compare the severity of atopic dermatitis, gut microbiota, and metabolite changes during the 6 days of mulberry juice consumption between the experimental and control groups.

This project will help establish mulberry fruit as a potential human prebiotic and adjunctive treatment for alleviating atopic dermatitis in children.

Read the detailed description

The results of animal experiments have confirmed that mulberry fruit can improve atopic dermatitis. Its anti-inflammatory response is associated with the regulation of innate immune pathways and the restoration of skin barrier function. Additionally, mulberry extract may have prebiotic effects, altering the gut microbiota and metabolites to improve host health. Currently, mulberries are known to contain a significant amount of glucosides, with interleukin-17 isomer modulation being a major component. Therefore, mulberry fruit may have immune-regulatory effects, especially in Asian children and adolescents with elevated Th-17-related interleukin expression. However, it is paucity in research on the anti-inflammatory effects of mulberry fruit and its impact on gut microbiota in human atopic dermatitis.

This project proposes a randomized controlled human study to explore the long-term effects of consuming mulberry juice on atopic dermatitis in children and adolescents, as well as the composition of gut microbiota and metabolites. The study aims to investigate the potential of mulberry fruit as a human prebiotic. A randomized controlled human study will recruit up to 120 participants from the Taipei Medical University Hospital (commissioned by the Ministry of Health and Welfare). Participants will be divided into experimental groups and a control group, with a 3-month intervention involving five clinical assessments and three stool collections. The goal is to compare the severity of atopic dermatitis, gut microbiota, and metabolite changes during the 3 months of mulberry juice consumption between the experimental and control groups.

This project will help establish mulberry fruit as a potential human prebiotic and adjunctive treatment for alleviating atopic dermatitis in children. It will also lay the foundation for future research on effective component isolation and analysis, elucidating the impact of mulberry fruit on the composition of the human gut microbiota and metabolites.

03

Conditions studied

  • Atopic Dermatitis (Eczema)
  • Atopic Dermatitis, Probiotics
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 6 years and above (including 6 years) to less than 18 years (excluding 18 years)
  • The legal guardian has the ability to understand and is willing to sign the written document
  • Diagnosed by a physician according to the international Hanifin \& Rajka criteria for atopic dermatitis, with a confirmed diagnosis of more than six months

Exclusion criteria

Exclusion Criteria:

  • Allergic to berries, mulberries, fruits from the same family (such as figs), or similar chemical or biological components
  • Patients with immunodeficiency, including congenital or acquired immune disorders
  • Patients with immune-related diseases other than allergies, asthma, or allergic rhinitis, including , rheumatic diseases, lupus erythematosus, chronic liver diseases, cirrhosis, kidney diseases, diabetes, or asplenia
  • Individuals with other diseases or mental disorders that prevent them from complying with the intervention plan
  • Patients with Short Bowel Syndrome
  • Received oral or injectable antibiotics in the past month
  • Received immunomodulators, biologics, or oral/injectable exceeding 2 mg/kg/day in the past three months
  • Underwent major surgery within 28 days before the study intervention (including the 28th day) or have not recovered from the side effects or complications of drug treatment/surgery from four weeks prior
  • Currently participating in other drug intervention studies
  • Currently experiencing systemic infection or unexplained fever (ear temperature greater than or equal to 38°C)
  • Pregnancy
  • Premature infants (born before 37 weeks, excluding 37 weeks)
  • Individuals with congenital diseases, nutritional or metabolic disorders, or keratinization disorders
  • Diagnosed with malignancies within the past five years.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Active comparator
    control arm

    standard atopic dermatitis treatment

    Other: Mometasone furoate 0.1% cream

  • Experimental
    experimental arm

    add-on 200 ml/day mulberry juice with standard therapy

    Dietary Supplement: Mulberry fruit juice

Interventions

  • Dietary supplementMulberry fruit juice

    Mulberry fruit juice 200ml/day plus standard therapy for atopic dermatitis including topical Mometasone furoate cream 0.1%

  • OtherMometasone furoate 0.1% cream

    Standard therapy for atopic dermatitis including Mometasone furoate cream 0.1%

06

What researchers measure

Primary outcomes

  1. Change of Metabolism

    Stool abundance statistical analysis at genus and species level, including richness, Chao1 index, Shannon and Simpson index, of gut microbiota from stool specimen collected from participants on 1st day and 8th day.

    Time frame: 6 days until completion of juice intake

Secondary outcomes

  1. Change of the Scoring Atopic Dermatitis (SCORAD)

    Evaluate the Scoring Atopic Dermatitis (SCORAD) scores on 1st day, 3rd, 6th, 9th and 12th week. The Score range is between 0 and 103 points and defines three classes of AD severity (i.e. mild if SCORAD \<25, moderate if 25 ≤ SCORAD ≤ 50 and severe if SCORAD \> 50)

    Time frame: From enrollment to the end of experiment at 12 weeks

  2. Change of the Children's Dermatology Life Quality Index (CDLQI)

    Evaluate the Children's Dermatology Life Quality Index (CDLQI) scores on 1st day, 3rd, 6th, 9th and 12th week. The minimum score is 0 and the maximum score is 30. Higher scores mean worse outcome.

    Time frame: From enrollment to the end of experiment at 12 weeks

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Feb 2026, 10 months after the start.

Of 114 non-industry interventional studies with no phase under Dermatitis, Atopic, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 10 months is below that.

Counting every sponsor, half of 183 studies reached it within 15 months; a quarter within 7 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2024
First posted
Oct 10, 2024
StartActual
Mar 17, 2025
Primary completionEst.
Feb 1, 2026
CompletionEst.
Apr 30, 2026
Last update
May 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06636240
Responsible party
Meng-Che Lu (Pediatric Immunologist, Taipei Medical University Shuang Ho Hospital) — Principal investigator
First posted
Oct 10, 2024
Start date
Mar 17, 2025
Primary completion
Feb 1, 2026 (estimated)
Completion
Apr 30, 2026 (estimated)
Last update
May 25, 2025

Study contacts

Meng-Che Lu, M.D.
Contact
13490@s.tmu.edu.tw
+886970747887
Yu-Yuan Huang, Associate degree
Contact
08123@s.tmu.edu.tw
Taipei Medical University Shuang Ho Hospital
principal investigator · Taipei Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion